Roxadustat in CKD and transplant patients: A new era in anemia management

The aim of this study was to evaluate the efficacy and safety of Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the management of anemia in patients with chronic kidney disease (CKD), including hemodialysis-dependent (HDD), non-dialysis-dependent (NDD), and renal...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Muhammad Tassaduq Khan, Sidrah Rashid, Syed Hasan farooq, Sabahat Sarfaraz, Rashid bin Hamid, Naranjan Lal
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Liaquat University of Medical and Health Sciences 2025-03-01
Serie:	Liaquat Medical Research Journal
Soggetti:	Roxadustat, Anemia, Chronic Kidney Disease, Hemoglobin, Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, Safety, Efficacy, Hemodialysis, Non-Dialysis, Renal Transplant.
Accesso online:	http://121.52.154.206/index.php/LMRJ/article/view/1284
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!